Julie Park1, Urmi Das1, Mohammed Didi1, Renuka Ramakrishnan1, Matthew Peak2, Paul Newland3, Joanne Blair4. 1. Department of Endocrinology, Alder Hey Children's NHS Foundation Trust, Liverpool, L12 2AP, UK. 2. NIHR Alder Hey Clinical Research Facility, Alder Hey Children's NHS Foundation Trust, Liverpool, UK. 3. Department of Clinical Biochemistry, Alder Hey Children's NHS Foundation Trust, Liverpool, UK. 4. Department of Endocrinology, Alder Hey Children's NHS Foundation Trust, Liverpool, L12 2AP, UK. jo.blair@alderhey.nhs.uk.
Abstract
BACKGROUND: Hydrocortisone is the preferred treatment for adrenal insufficiency in childhood. A small minority of children experience low cortisol concentrations and symptoms of cortisol insufficiency, poorly responsive to modifications in dosing. We speculated that treatment with modified-release hydrocortisone Plenadren® may be beneficial in these selected patients. OBJECTIVE: The aim of this article was to report cortisol profiles during treatment with standard formulation hydrocortisone and Plenadren, and growth and weight gain during treatment with Plenadren in selected children with adrenal insufficiency. PATIENTS AND METHODS: Data are reported as median (range). Eight patients (5 male) age 11.0 years (8.8-13.3), with adrenal insufficiency for 4.3 years (2.2-10.0) were treated with Plenadren in doses derived from cortisol concentrations measured during treatment with standard formulation hydrocortisone. RESULTS: Plasma cortisol was 262 nmol/L (114-654) 2 h after the morning dose (hydrocortisone dose 6.1 mg/m2 [4.3-7.1]) of standard formulation hydrocortisone. After 4 h, cortisol concentration was 81 nmol/L (56-104) and was < 100 nmol/L in six patients. Two hours after Plenadren administration (hydrocortisone dose 12.1 mg/m2 [8.3-17.6]), plasma cortisol concentration was 349 nmol/L (150-466), and after 4 h it was 239 nmol/L (99-375) and < 100 nmol/L in one patient. Six hours after the Plenadren dose, cortisol concentration was < 100 nmol/L in four patients and after 8 h cortisol concentration was < 100 nmol/L in seven patients (sample not obtained in one patient). Six patients elected to continue treatment with Plenadren. After 4.2 years (2.7-6.0), change in height standard deviation score (SDS) was 0.1 SD (- 0.2 to 0.2) and body mass index SDS was 0.3 SD (0-1.1). CONCLUSION: Smoother cortisol profiles and more sustained cortisol exposure were achieved during treatment with Plenadren, which was the preferred treatment in most patients. Robust clinical trials are required to determine the place of this medication in paediatric practice.
BACKGROUND:Hydrocortisone is the preferred treatment for adrenal insufficiency in childhood. A small minority of children experience low cortisol concentrations and symptoms of cortisol insufficiency, poorly responsive to modifications in dosing. We speculated that treatment with modified-release hydrocortisonePlenadren® may be beneficial in these selected patients. OBJECTIVE: The aim of this article was to report cortisol profiles during treatment with standard formulation hydrocortisone and Plenadren, and growth and weight gain during treatment with Plenadren in selected children with adrenal insufficiency. PATIENTS AND METHODS: Data are reported as median (range). Eight patients (5 male) age 11.0 years (8.8-13.3), with adrenal insufficiency for 4.3 years (2.2-10.0) were treated with Plenadren in doses derived from cortisol concentrations measured during treatment with standard formulation hydrocortisone. RESULTS: Plasma cortisol was 262 nmol/L (114-654) 2 h after the morning dose (hydrocortisone dose 6.1 mg/m2 [4.3-7.1]) of standard formulation hydrocortisone. After 4 h, cortisol concentration was 81 nmol/L (56-104) and was < 100 nmol/L in six patients. Two hours after Plenadren administration (hydrocortisone dose 12.1 mg/m2 [8.3-17.6]), plasma cortisol concentration was 349 nmol/L (150-466), and after 4 h it was 239 nmol/L (99-375) and < 100 nmol/L in one patient. Six hours after the Plenadren dose, cortisol concentration was < 100 nmol/L in four patients and after 8 h cortisol concentration was < 100 nmol/L in seven patients (sample not obtained in one patient). Six patients elected to continue treatment with Plenadren. After 4.2 years (2.7-6.0), change in height standard deviation score (SDS) was 0.1 SD (- 0.2 to 0.2) and body mass index SDS was 0.3 SD (0-1.1). CONCLUSION: Smoother cortisol profiles and more sustained cortisol exposure were achieved during treatment with Plenadren, which was the preferred treatment in most patients. Robust clinical trials are required to determine the place of this medication in paediatric practice.
Authors: S V Gelding; N F Taylor; P J Wood; K Noonan; J U Weaver; D F Wood; J P Monson Journal: Clin Endocrinol (Oxf) Date: 1998-02 Impact factor: 3.478
Authors: Alberto M Marra; Nicola Improda; Donatella Capalbo; Andrea Salzano; Michele Arcopinto; Amato De Paulis; Maria Alessio; Andrea Lenzi; Andrea M Isidori; Antonio Cittadini; Mariacarolina Salerno Journal: J Clin Endocrinol Metab Date: 2014-11-18 Impact factor: 5.958
Authors: G Johannsson; A G Nilsson; R Bergthorsdottir; P Burman; P Dahlqvist; B Ekman; B E Engström; T Olsson; O Ragnarsson; M Ryberg; J Wahlberg; B M K Biller; J P Monson; P M Stewart; H Lennernäs; S Skrtic Journal: J Clin Endocrinol Metab Date: 2011-11-23 Impact factor: 5.958
Authors: Jorien Werumeus Buning; Daan J Touw; Pauline Brummelman; Robin P F Dullaart; Gerrit van den Berg; Melanie M van der Klauw; Jasper Kamp; Bruce H R Wolffenbuttel; André P van Beek Journal: Metabolism Date: 2017-02-13 Impact factor: 8.694
Authors: John G Lewis; Christopher J Bagley; Peter A Elder; Anthony W Bachmann; David J Torpy Journal: Clin Chim Acta Date: 2005-09 Impact factor: 3.786
Authors: Evangelia Charmandari; Martina Weise; Stefan R Bornstein; Graeme Eisenhofer; Margaret F Keil; George P Chrousos; Deborah P Merke Journal: J Clin Endocrinol Metab Date: 2002-05 Impact factor: 5.958
Authors: M Tschöp; H Lahner; H Feldmeier; H Grasberger; K M Morrison; O E Janssen; A F Attanasio; C J Strasburger Journal: Eur J Endocrinol Date: 2000-12 Impact factor: 6.664
Authors: Daniel Luis Schueftan Gilban; Paulo Alonso Garcia Alves Junior; Izabel Calland Ricarte Beserra Journal: Health Qual Life Outcomes Date: 2014-08-13 Impact factor: 3.186
Authors: Arundoss Gangadharan; Paul McCoy; Aye Phyo; Michael P McGuigan; Poonam Dharmaraj; Renuka Ramakrishnan; Paul S McNamara; Joanne Blair Journal: J Asthma Allergy Date: 2017-12-15